Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis

Amit A. Kulkarni; Cassandra Hennessy; Grace Wilson; Vidhyalakshmi Ramesh; Clara Hwang; Joy Awosika; Ziad Bakouny; Hina Khan; Diana Vilar-Compte; Rana McKay; Chinmay Jani; Lisa Weissmann; Elizabeth Griffiths; Gerald Batist; Nathaniel Bouganim; Blanche Mavromatis; Babar Bashir; Ryan H. Nguyen; Jonathan W. Riess; Matthew Puc; Anup Kasi; Stephanie Berg; Dan Ran Castillo; Brandon Hayes-Lattin; Wylie Hosmer; Daniel Flora; Sanjay Mishra; Benjamin French; Jeremy L. Warner; Gilberto Lopes; Solange Peters; Narjust Florez

doi:10.1016/j.cllc.2024.04.003

Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis

Amit A. Kulkarni, Cassandra Hennessy, Grace Wilson, Vidhyalakshmi Ramesh, Clara Hwang, Joy Awosika, Ziad Bakouny, Hina Khan, Diana Vilar-Compte, Rana McKay, Chinmay Jani, Lisa Weissmann, Elizabeth Griffiths, Gerald Batist, Nathaniel Bouganim, Blanche Mavromatis, Babar Bashir, Ryan H. Nguyen, Jonathan W. Riess, Matthew PucAnup Kasi, Stephanie Berg, Dan Ran Castillo, Brandon Hayes-Lattin, Wylie Hosmer, Daniel Flora, Sanjay Mishra, Benjamin French, Jeremy L. Warner, Gilberto Lopes, Solange Peters, Narjust Florez

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with thoracic cancers and COVID-19 have high mortality and morbidity. • Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited. • We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19). • As opposed to immunotherapy or targeted therapy, recent (<3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity. • None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality. • Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.

Original language	English (US)
Pages (from-to)	e229-e237.e7
Journal	Clinical Lung Cancer
Volume	25
Issue number	5
DOIs	https://doi.org/10.1016/j.cllc.2024.04.003
State	Published - Jul 2024

Bibliographical note

Publisher Copyright:
© 2024 Elsevier Inc.

Keywords

Chemotherapy
Immunotherapy
Targeted therapy
Thoracic Cancers

PubMed: MeSH publication types

Case Reports
Journal Article

Publisher link

10.1016/j.cllc.2024.04.003

Find It

Find It at U of M Libraries

Cite this

Kulkarni, A. A., Hennessy, C., Wilson, G., Ramesh, V., Hwang, C., Awosika, J., Bakouny, Z., Khan, H., Vilar-Compte, D., McKay, R., Jani, C., Weissmann, L., Griffiths, E., Batist, G., Bouganim, N., Mavromatis, B., Bashir, B., Nguyen, R. H., Riess, J. W., ... Florez, N. (2024). Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis. Clinical Lung Cancer, 25(5), e229-e237.e7. https://doi.org/10.1016/j.cllc.2024.04.003

Kulkarni, AA, Hennessy, C, Wilson, G, Ramesh, V, Hwang, C, Awosika, J, Bakouny, Z, Khan, H, Vilar-Compte, D, McKay, R, Jani, C, Weissmann, L, Griffiths, E, Batist, G, Bouganim, N, Mavromatis, B, Bashir, B, Nguyen, RH, Riess, JW, Puc, M, Kasi, A, Berg, S, Castillo, DR, Hayes-Lattin, B, Hosmer, W, Flora, D, Mishra, S, French, B, Warner, JL, Lopes, G, Peters, S & Florez, N 2024, 'Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis', Clinical Lung Cancer, vol. 25, no. 5, pp. e229-e237.e7. https://doi.org/10.1016/j.cllc.2024.04.003

@article{c15da3094a8a4e6680d8ed143a2fd235,

title = "Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis",

abstract = "Patients with thoracic cancers and COVID-19 have high mortality and morbidity. • Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited. • We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19). • As opposed to immunotherapy or targeted therapy, recent (<3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity. • None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality. • Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.",

keywords = "Chemotherapy, Immunotherapy, Targeted therapy, Thoracic Cancers",

author = "Kulkarni, {Amit A.} and Cassandra Hennessy and Grace Wilson and Vidhyalakshmi Ramesh and Clara Hwang and Joy Awosika and Ziad Bakouny and Hina Khan and Diana Vilar-Compte and Rana McKay and Chinmay Jani and Lisa Weissmann and Elizabeth Griffiths and Gerald Batist and Nathaniel Bouganim and Blanche Mavromatis and Babar Bashir and Nguyen, {Ryan H.} and Riess, {Jonathan W.} and Matthew Puc and Anup Kasi and Stephanie Berg and Castillo, {Dan Ran} and Brandon Hayes-Lattin and Wylie Hosmer and Daniel Flora and Sanjay Mishra and Benjamin French and Warner, {Jeremy L.} and Gilberto Lopes and Solange Peters and Narjust Florez",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Inc.",

year = "2024",

month = jul,

doi = "10.1016/j.cllc.2024.04.003",

language = "English (US)",

volume = "25",

pages = "e229--e237.e7",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Brief Report

T2 - Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis

AU - Kulkarni, Amit A.

AU - Hennessy, Cassandra

AU - Wilson, Grace

AU - Ramesh, Vidhyalakshmi

AU - Hwang, Clara

AU - Awosika, Joy

AU - Bakouny, Ziad

AU - Khan, Hina

AU - Vilar-Compte, Diana

AU - McKay, Rana

AU - Jani, Chinmay

AU - Weissmann, Lisa

AU - Griffiths, Elizabeth

AU - Batist, Gerald

AU - Bouganim, Nathaniel

AU - Mavromatis, Blanche

AU - Bashir, Babar

AU - Nguyen, Ryan H.

AU - Riess, Jonathan W.

AU - Puc, Matthew

AU - Kasi, Anup

AU - Berg, Stephanie

AU - Castillo, Dan Ran

AU - Hayes-Lattin, Brandon

AU - Hosmer, Wylie

AU - Flora, Daniel

AU - Mishra, Sanjay

AU - French, Benjamin

AU - Warner, Jeremy L.

AU - Lopes, Gilberto

AU - Peters, Solange

AU - Florez, Narjust

PY - 2024/7

Y1 - 2024/7

N2 - Patients with thoracic cancers and COVID-19 have high mortality and morbidity. • Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited. • We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19). • As opposed to immunotherapy or targeted therapy, recent (<3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity. • None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality. • Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.

AB - Patients with thoracic cancers and COVID-19 have high mortality and morbidity. • Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited. • We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19). • As opposed to immunotherapy or targeted therapy, recent (<3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity. • None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality. • Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.

KW - Chemotherapy

KW - Immunotherapy

KW - Targeted therapy

KW - Thoracic Cancers

UR - http://www.scopus.com/inward/record.url?scp=85192718832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85192718832&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2024.04.003

DO - 10.1016/j.cllc.2024.04.003

M3 - Article

C2 - 38744613

AN - SCOPUS:85192718832

SN - 1525-7304

VL - 25

SP - e229-e237.e7

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 5

ER -

Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this